Clinical UpdatesamycretinGLP-1 receptor agonist
Amycretin: A Promising First-in-Class Dual GLP-1 and Amylin Receptor Agonist for Overweight and Obesity
By MedXY|Oct 8, 2025
Amycretin, a novel dual GLP-1 and amylin receptor agonist, demonstrated safety, tolerability, and dose-proportional pharmacokinetics in adults with overweight or obesity, supporting further trials on its weight loss efficacy.
